Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cue Biopharma, Inc. on February 9, 2020, covering events occurring on February 9 and February 10, 2020. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Cambridge, Massachusetts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on corporate governance and executive compensation rather than periodic financial performance.
Material Changes
- Executive Compensation: On February 10, 2020, the Company entered into a Second Amended and Restated Employment Agreement with CEO Daniel Passeri. His salary was increased to $515,000, and his employment term was extended to March 31, 2021.
- Equity Grants: In connection with the new agreement, Mr. Passeri received a grant of 150,000 stock options and 150,000 restricted stock units.
- Board Resignations: On February 9, 2020, Chris Marlett and Steven McKnight resigned from the Board of Directors. The Board size was reduced to seven members. The resignations were not due to any disagreement with the Company.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or management commentary regarding future operations. No specific risks or contingencies were disclosed in this report other than the standard reference to the full employment agreement exhibit.
Key Facts for Investor Verification
- Verify the total dilution impact of the 300,000 equity units (options and RSUs) granted to the CEO.
- Confirm the current composition of the Board of Directors following the reduction to seven members.
- Review the full text of the Second Amended and Restated Employment Agreement (Exhibit 10.1) for severance provisions and performance conditions.